Press Releases
This section of Viatris.com contains information that may not be suitable for use in all countries due to varied regulatory requirements, data protection requirements and practices or medical practices, and distinctions among product approval and commercial availability. The information contained in each news release or statement posted on this page is presented as of the date it was issued. The company undertakes no obligation to update the information for changes or subsequent events after the date it was originally issued.
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Dec 1, 2021Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent
- Nov 18, 2021Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference
- Nov 16, 2021Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) InjectionBranded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
- Nov 11, 2021Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted CommunitiesThe multi-year impact investment will rebuild homes for at least 50 veterans
- Nov 8, 2021Viatris Reports Strong Third Quarter Results, Raises 2021 Financial Guidance and Announces Virtual Investor Event on January 7, 2022Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share
- Oct 20, 2021Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest FormularyUpcoming launch of two interchangeable biosimilar insulin glargine injection options co-developed with Biocon Biologics will help increase access to critical treatment for millions of Americans living with diabetes
- Oct 13, 2021Viatris Inc. to Release Third Quarter 2021 Financial Results on Nov. 8, 2021
- Oct 11, 2021Viatris Named Fifth on Fortune's Change the World ListFortune Recognizes Viatris for Expanding Access to Innovative HIV Medicines, Particularly in Low- and Middle-income Countries
- Aug 30, 2021Viatris Inc. to Participate in BofA Global Healthcare Conference
- Aug 30, 2021Viatris Inc. to Participate in Citi's 16th Annual BioPharma Conference
- Aug 9, 2021Viatris Reports Strong Second Quarter ResultsBoard of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share
- Jul 28, 2021Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn) injection for the Treatment of DiabetesInterchangeable Designation Allows Substitution at the Pharmacy Counter for Lantus® Across the U.S. to Help Increase Access to Medicines for People Living with Diabetes
- Jul 27, 2021Mylan Wins Dismissal of Kansas EpiPen® Direct Purchaser Case
- Jul 8, 2021Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021
- Jun 23, 2021Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class ActionCompany Confident Evidence Regarding Only Remaining Claim Will Show Mylan's Actions Were Lawful and Pro-competitive
- May 25, 2021Viatris Inc. to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
- May 10, 2021Viatris Inc. Reports Strong First Quarter 2021 Financial Results, Reaffirms 2021 Guidance and Announces Inaugural Quarterly Dividend
- May 6, 2021Viatris Inc. Releases Inaugural Sustainability Report, Reinforcing its Commitment to Better Health and Better Communities WorldwideNew company highlights patients, holistic approach to providing access to medicine, and path to further progress
- Apr 30, 2021Viatris Inc. to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
- Apr 29, 2021Viatris Inc. to Participate in BofA Securities 2021 Health Care Conference
- Apr 28, 2021Viatris Inc. and Atomo Diagnostics Announce Agreement with Unitaid to Expand Access to HIV Self-Test
- Apr 12, 2021Viatris Inc. to Release First Quarter 2021 Financial Results on May 10, 2021
- Mar 8, 2021Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation AerosolMilestone reinforces Viatris' commitment to complex products and innovative solutions to help increase patient access
- Mar 4, 2021Viatris Inc. to Participate in Barclays Global Healthcare Conference
- Mar 1, 2021Viatris Inc. Hosts Inaugural Investor Day Outlining Unique and Differentiated Business Model, High-Quality Operational Platform, and Focus on CSR and Financial Commitments